83148-55-4

Upstream product

• 29670-63-1 N-benzoyl-2-phenylglycine 
• 83084-67-7 2-Phenyl-4-benzyl-4-β-carbomethoxypropionyloxazolone 
• 5874-61-3 4-benzyl-2-phenyl-2-oxazolin-5-one 
• 77982-73-1 (R,S)-5-benzoylamino-4-oxo-6-phenylhexanoic acid methyl ester 

Downstream Products

• 83084-68-8 5-Amino-4-oxo-6-phenyl-hexanoic acid methyl ester 
• 77921-47-2 (S)-1-<5-(benzoylamino)-4-(hydroxyimino)-1-oxo-6-phenylhexyl>-L-proline 
• 77921-60-9 (S)-1-((S)-5-Acetylamino-4-oxo-6-phenyl-hexanoyl)-pyrrolidine-2-carboxylic acid 
• 83148-73-6 δ-(acetylamino)-γ-oxobenzenehexanoic acid 
• 100242-07-7 methyl 5-amino-4-oxo-6-phenylhexanoate hydrochloride 
• 83450-73-1 (S)-1-((S)-5-Decanoylamino-4-oxo-6-phenyl-hexanoyl)-pyrrolidine-2-carboxylic acid 
• 83509-06-2 (S)-1-((S)-5-Octanoylamino-4-oxo-6-phenyl-hexanoyl)-pyrrolidine-2-carboxylic acid 
• 83084-86-0 5-n-butyloxycarbonylamino-4-oxo-6-phenylhexanoyl-L-proline 
• 83084-94-0 (S)-1-((S)-5-Hexanoylamino-4-oxo-6-phenyl-hexanoyl)-pyrrolidine-2-carboxylic acid 
• 83450-72-0 5-Decanoylamino-4-oxo-6-phenyl-hexanoic acid methyl ester 
• 83450-71-9 5-Octanoylamino-4-oxo-6-phenyl-hexanoic acid methyl ester 
• 83450-63-9 methyl 5-<(n-butyloxycarbonyl)amino>-4-oxo-6-phenylhexanoate 
• 83450-70-8 5-Hexanoylamino-4-oxo-6-phenyl-hexanoic acid methyl ester 
• 99595-02-5 N-benzoyl-(RS)Pheψ(COCH2)Gly-Leu-Met-NH2 

Relevant academic research and scientific papers

The Synthesis of Methyl 5-Benzoylamino-4-oxo-6-phenylhexanoate by a Direct Dakin-West Reaction

The title substance was synthesized in 84percent yield by a direct Dakin-West reaction involving N-benzoylphenylalanine, 3,3'-dimethoxycarbonylpropanoic anhydride (the anhydride of methyl hydrogen succinate), and pyridine.

Derivatives of the potent angiotensin converting enzyme inhibotor 5(S)-benzamido-4-oxo-6-phenylhexanoyl-L-proline: Effect of changes at positions 2 and 5 of the hexanoic acid portion

Several derivatives of the potent angiotensin converting enzyme inhibitor 5(S)-benzamido-4-oxo-6-phenylhexanoyl-L-proline (1) were synthesized and tested for converting enzyme inhibition activity and blood pressure lowering effects in rats. One compound, 5(S)-benzamido-2(R)-methyl-4-oxo-6-phenylhexanoyl-L-proline (2a), had an I50 against angiotensin converting enzyme of 1.0 x 10-9 M and is the most potent inhibitor prepared thus far in this class of compounds. Testing of 2a orally at 30 mg/kg for inhibition of the angiotensin I induced blood pressure increase in conscious normotensive rats gave 100% inhibition that required 143 min before the angiotensin I blood pressure response returned to 70% of the pretreatment control response. In the conscious renal hypertensive rat, 2a given orally at a dose of 3 mg/kg caused a lowering of blood pressure that reached its maximum of 40 mmHg 8 h following drug administration.